These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 34117917)
1. Anticancer activity of Helicobacter pylori ribosomal protein (HPRP) with iRGD in treatment of colon cancer. Yaghoubi A; Asgharzadeh F; Movaqar A; Ghazvini K; Hassanian SM; Avan A; Khazaei M; Soleimanpour S J Cancer Res Clin Oncol; 2021 Oct; 147(10):2851-2865. PubMed ID: 34117917 [TBL] [Abstract][Full Text] [Related]
2. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation. Hu C; Huang Y; Chen Y Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418 [TBL] [Abstract][Full Text] [Related]
3. Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability. Hu C; Chen X; Huang Y; Chen Y Sci Rep; 2018 Feb; 8(1):2274. PubMed ID: 29396568 [TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon. Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258 [TBL] [Abstract][Full Text] [Related]
5. TAT Modification of Alpha-Helical Anticancer Peptides to Improve Specificity and Efficacy. Hao X; Yan Q; Zhao J; Wang W; Huang Y; Chen Y PLoS One; 2015; 10(9):e0138911. PubMed ID: 26405806 [TBL] [Abstract][Full Text] [Related]
6. Ginsenoside Rg3 enhances the anticancer effect of 5‑FU in colon cancer cells via the PI3K/AKT pathway. Hong S; Cai W; Huang Z; Wang Y; Mi X; Huang Y; Lin Z; Chen X Oncol Rep; 2020 Oct; 44(4):1333-1342. PubMed ID: 32945504 [TBL] [Abstract][Full Text] [Related]
8. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Touil Y; Igoudjil W; Corvaisier M; Dessein AF; Vandomme J; Monté D; Stechly L; Skrypek N; Langlois C; Grard G; Millet G; Leteurtre E; Dumont P; Truant S; Pruvot FR; Hebbar M; Fan F; Ellis LM; Formstecher P; Van Seuningen I; Gespach C; Polakowska R; Huet G Clin Cancer Res; 2014 Feb; 20(4):837-46. PubMed ID: 24323901 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Grassilli E; Narloch R; Federzoni E; Ianzano L; Pisano F; Giovannoni R; Romano G; Masiero L; Leone BE; Bonin S; Donada M; Stanta G; Helin K; Lavitrano M Clin Cancer Res; 2013 Jul; 19(14):3820-31. PubMed ID: 23729362 [TBL] [Abstract][Full Text] [Related]
10. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice. Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139 [TBL] [Abstract][Full Text] [Related]
11. Synergistic therapeutic effects of Schiff's base cross-linked injectable hydrogels for local co-delivery of metformin and 5-fluorouracil in a mouse colon carcinoma model. Wu X; He C; Wu Y; Chen X Biomaterials; 2016 Jan; 75():148-162. PubMed ID: 26497429 [TBL] [Abstract][Full Text] [Related]
12. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Arango D; Corner GA; Wadler S; Catalano PJ; Augenlicht LH Cancer Res; 2001 Jun; 61(12):4910-5. PubMed ID: 11406570 [TBL] [Abstract][Full Text] [Related]
13. Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. Shimoyama S; Mochizuki Y; Kusada O; Kaminishi M Int J Oncol; 2002 Sep; 21(3):643-8. PubMed ID: 12168112 [TBL] [Abstract][Full Text] [Related]
14. The effects of 5-fluorouracil on the proteome of colon cancer cells. Marin-Vicente C; Lyutvinskiy Y; Romans Fuertes P; Zubarev RA; Visa N J Proteome Res; 2013 Apr; 12(4):1969-79. PubMed ID: 23477467 [TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of the pro-apoptosis peptide kla-TAT and the cationic anticancer peptide HPRP-A1. Hu C; Chen X; Huang Y; Chen Y Apoptosis; 2018 Feb; 23(2):132-142. PubMed ID: 29397453 [TBL] [Abstract][Full Text] [Related]
16. Annexin A1 is involved in resistance to 5-FU in colon cancer cells. Onozawa H; Saito M; Saito K; Kanke Y; Watanabe Y; Hayase S; Sakamoto W; Ishigame T; Momma T; Ohki S; Takenoshita S Oncol Rep; 2017 Jan; 37(1):235-240. PubMed ID: 27840982 [TBL] [Abstract][Full Text] [Related]
17. Conditioned media from human macrophages of M1 phenotype attenuate the cytotoxic effect of 5‑fluorouracil on the HT‑29 colon cancer cell line. Hedbrant A; Erlandsson A; Delbro D; Wijkander J Int J Oncol; 2015 Jan; 46(1):37-46. PubMed ID: 25310018 [TBL] [Abstract][Full Text] [Related]
18. Coadministration of kla peptide with HPRP-A1 to enhance anticancer activity. Hao W; Hu C; Huang Y; Chen Y PLoS One; 2019; 14(11):e0223738. PubMed ID: 31703065 [TBL] [Abstract][Full Text] [Related]
19. BET Inhibitors Potentiate Chemotherapy and Killing of Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532 [TBL] [Abstract][Full Text] [Related]
20. Anticancer activity of Yaghoubi A; Movaqar A; Asgharzadeh F; Derakhshan M; Ghazvini K; Hasanian SM; Avan A; Mostafapour A; Khazaei M; Soleimanpour S Iran J Basic Med Sci; 2023; 26(7):768-776. PubMed ID: 37396945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]